Abstract (Resource Core): The goal of the TRaCe-bMPS Center is to take five validated microphysiological systems (bMPS) built on the µSiM (microphysiological system featuring a Silicon Membrane) tissue chip platform through the process of qualification as FDA-approved Drug Discovery Tools (DDTs). Accomplishing this goal will require consistent access to well-characterized cells, biomolecules, and device components; curated standard operating procedures (SOPs) and protocols that can be shared between researchers replicating data; and methods for scaling manufacturing of the DDTs undergoing qualification. To address these needs, we propose to establish a Resource Core that will work in close collaboration with the Qualification Program and Administrative Core to ensure that quality control measures are consistently implemented, SOPs and protocols are developed and finalized, and manufacturing scaleup is addressed. The Resource core will also lead development of new device versions compatible with automated laboratory instrumentation and will support outreach and resource sharing with academia and industry to facilitate Center sustainability. Four Aims will be completed: Aim 1: Serve as a source of well-characterized cells, biomolecules, other reagents, and structural components used in TRaCe-bMPS devices and assays. Aim 2: Develop a central repository of designs, protocols, and SOPs for TrACe-bMPS devices and assays, and provide cross-consortium training. Aim 3: Scale DDTs to independently addressable parallel formats (1 x 4 strip format) for medium-throughput analyses compatible with industry-standard liquid handling and including photonic sensing of secreted proteins, and develop methods for manufacturing scaleup. Aim 4: Establish industrial and academic partnerships to strengthen the TRaCe-bMPS consortium and support resource sharing. This will include support, including access to materials, for researchers outside the Center to use µSiM-bMPS technology in their own research.